Completado

PCOLetrozole Versus Clomiphene Citrate Plus Metformin in the First Treatment of Infertility in Patients With Polycystic Ovarian Syndrome

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

Letrozole

+ Clomiphene

+ Metformin

Medicamento
Quiénes están siendo reclutados

Enfermedades Urogenitales+9

+ Enfermedades Genitales

+ Enfermedades Anexiales

De 18 a 35 años
+6 Criterios de eligibilidad
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Intervencional
Inicio del estudio: enero de 2009
Ver detalles del protocolo

Resumen

Patrocinador PrincipalAssiut University
Última actualización: 7 de septiembre de 2012
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de enero de 2009

Fecha en la que se inscribió al primer participante.

The study will be in 200 patient diagnosed to have PCOS among those attending the Fertility Outpatient Clinic at the Women's Health Center, Assiut University Hospitals. The present study was prospective randomized controlled trial conducted over a period of 3 years from 1st of January 2009 to 1st of January 2012, at the Women's Health Center, Assiut University hospital, Assiut, Egypt, after approval was received from the Ethics Committee of faculty of medicine , Assiut University. Women referred to the infertility clinic in women's health center were screened for PCO using Rotterdam consensus criteria for the diagnosis of PCOS. The patients who were newly diagnosed as PCO and not treated previously were invited to participate in our study. Written informed consent was obtained from each participant after an information sheet had been provided. The patients had the right to refuse participation in the study or to withdraw at any time without being denied their full regular clinical care. All personal information and medical data were confidential and were not made available to third parties. All participants met the Rotterdam consensus criteria for the diagnosis of PCOS. At admission, a thorough medical history was taken and all women underwent physical examination, which included anthropometric measurements and after spontaneous menstruation or progestin induced withdrawal bleeding, basal endocrine evaluation on day 3 of the cycle included measurement of the serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH),thyroid stimulating hormone(TSH ) and prolactin. Then vaginal sonographic examination were done to measure endometrial thickness and exclude cases endometrial pathology or baseline ovarian cysts. The participants were randomized to receive letrozole or clomiphene citrate plus metformin. Randomization was performed using a computer-generated random numbers table, and allocation concealment was achieved using serially numbered opaque envelopes that were only opened once the interventions were assigned. In the letrozole group, the ovaries were stimulated using 2.5mg/day letrozole (Femara; Novartis Pharma, Basel, Switzerland) for 5 days,in the form of one tablet( 2.5 mg) per day for 5 days from day 3 to day 7 of the menstrual cycle and if ovulation has occurred with no pregnancy continue on the same dose for another 2 consecutive cycles ,but if no ovulation increase the dose to 2 tablets per day(5 mg) for another 2 consecutive cycles in the same manner . The patients in the second group will take metformin (Cidophage tablets,500 mg per tablet; CID, ARE, in an oral dose of 1,500 mg/d) 500mg three times daily for 3 months Plus clomid(50-mg tablets twice daily; Global Napi Pharmaceuticals, Cairo, Egypt , Arab Republic of Egypt) In the form of 50 mg twice daily (100mg /day) for 5 days from day 3 to day 7 of menstrual cycle and to be repeated for 3 consecutive cycles in the same manner if no pregnancy occur. In both groups, endometrial thickness and mean follicular diameter were assessed by the same investigator using transvaginal ultrasound on days 2 ,10, 12, and 14 of the menstrual cycle, and 10 000 IU of human chorionic gonadotropin (hCG) (Pregnyl; Organon, Oss, The Netherlands) were injected intramuscularly if there was at least 1 leading follicle measuring 18 mm or more in diameter and endometrial thickness detected at that time(endometrial thickness was determined at the greatest diameter perpendicular to the midsagittal plane in the fundal region, including both layers of the endometrium). All participants were advised to have intercourse 24-36 hours after the hCG injection. Two days after being given Human chorionic gonadotropin, the patients were assessed for signs of ovulation (disappearance of preovulatory follicle, fluid in the cul-de-sac, and/or corpus luteum formation). Pregnancy will be diagnosed when positive pregnancy test in urine done or a gestational sac was detected on transvaginal ultrasound examination 1week after the missed period or serum β-hCG concentration 14 days after HCG injection if menses had not occurred. A biochemical pregnancy was considered when the serum β-hCG concentration was 50 mIU/mL or more in the absence of menstruation. All study medication were stopped when there was positive pregnancy test.Pregnant patients then will be followed up until an ultrasound could document the viability of pregnancy. A clinical pregnancy was defined as the presence of a gestational sac with a beating fetal heart on transvaginal ultrasound. A spontaneous abortion was defined as the spontaneous loss of a pregnancy before the end of the 20th week.

Patrocinador PrincipalAssiut University
Última actualización: 7 de septiembre de 2012
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 200 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Mujer

Sexo biológico de los participantes elegibles para inscribirse.

De 18 a 35 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Enfermedades UrogenitalesEnfermedades GenitalesEnfermedades AnexialesQuistesEnfermedades del Sistema EndocrinoEnfermedades Urogenitales Femeninas y Complicaciones del EmbarazoEnfermedades Genitales FemeninasTrastornos GonadalesNeoplasiasQuistes OváricosEnfermedades del OvarioSíndrome de Ovario Poliquístico

Criterios

3 criterios de inclusión requeridos para participar
All participants met the Rotterdam consensus criteria for the diagnosis of PCOS . .Primary infertility because of anovulation for at least 1 year

Each woman was required to have patent tubes on hysterosalpingography or on a diagnostic laparoscopy

Only fresh (not treated previously) cases were recruited. .The male partner of each participant was required to have a normal result on semen analysis (count > 20million/ml,motility > 40%and normal morphology > 30%)

3 criterios de exclusión impiden participar
Age below 18 years or above 35 years , trial of ovulation induction prior to the stud ,BMI > 35

History of abdominal surgery that might have caused pelvic factor infertility

Presence of other causes of infertility; hyperprolactinemia (morning plasma prolactin concentration 30 ng/mL or more); any other endocrine, hepatic, or renal disorder; presence of an organic pelvic mass

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days

Grupo II

Comparador Activo
.Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene una ubicación

Assiut University

Asyut, EgyptAbrir Assiut University en Google Maps
Completado1 Centros de Estudio